Stephens & Associates
Richardson, Texas, 45081, United States
NCT Number: NCT02646917
This single-center, clinical trial will take place over a 90 day course followed by 1-month and 6-month post treatment visits to assess the efficacy and tolerability of the SkinPen device when used on both men and women on the face and/or back.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Not applicable
Richardson, Texas, 45081, United States
At least 20 subjects of varying Fitzpatrick skin types will be admitted to the trial for treatment on their moderate to severe acne scars on the face and/or back. Implementation of needle depths ranging from 0.25 mm to 2.0 mm will depend on severity of scars and their location. Each subject will undergo 3 treatments in 30 day increments and will take pre-treatment images as well as 1-month and 6-months post treatment images. Assessment will be based on the Goodman and Baron's grading system, the Clinician's Global Aesthetic Improvement Scale, as well as a self-assessment.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Treatment of acne scars on the face and/or back at needle depth settings ranging between 0.25 mm to 2.0 mm, depending on severity and location of scarring.
Time frame: Baseline, 1 month post treatment, and 6 months post treatment
Goodman and Baron's Qualitative grading system. Possible scores range from 1 = mild to 4 = severe.
Time frame: 1 month post treatment, and 6 months post treatment
Clinician's Global Aesthetic Improvement Assessment:
minimal score is 1- Very much improved and, maximum score is 5 -Worse: The appearance is worse than the original condition
Time frame: Day 1 (Baseline), Day 30, Day 60, 1-Month post treatment and 6 Month post treatment
Photo grading of acne scars assessment was done using the following scale [Karnik J. et al, JAAD 2014, 71 (1)]:
Grade- Term- Description
0 - Clear-- No depression is seen in the treatment area. Macular discoloration may be seen.
3- Moderate-- More than half of the depressions are apparent with direct lighting (deep)
4- Severe-- All or almost all the lesions can be seen with direct lighting (deep)
Time frame: One Month Post Treatment, 6 Month Post Treatment
Subject self-assessment was completed in 2 steps for self-assessed scar improvement scale (SASIS) and subject global aesthetic improvement scale (SGAIS):
Time frame: 1-Month Post Treatment and 6- Month Post Treatment
The following rating scale was used for SGAIS:
Rating and Description
Bellus Medical, LLC
Industry
A Single-Center Trial to Evaluate the Efficacy and Tolerability of SkinPen on Male and Female Subjects' Acne Scars on the Face and/or Back
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07028567
Atrophic Acne Scar, Calcium Hydroxylapatite
Tanta, El-Gharbia, Egypt
View Trial DetailsNCT06789874
Atrophic Acne Scar, Atrophic Acne Scarring
Rahimyarkhan, Punjab Province, Pakistan
View Trial DetailsNCT06580691
Acne Vulgaris, Acneiform Eruptions
Tanta, Gharbia Governorate, Egypt
View Trial DetailsNCT04740268
Atrophic Acne Scar
New York, United States
View Trial Details